Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 1:45 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,237 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: HIV Infected Clear all
Completed Phase 2 Interventional

Treatment Success and Failure in HIV-Infected Subjects Receiving Indinavir in Combination With Nucleoside Analogs: A Rollover Study for ACTG 320

NCT00000885
View directory record Official record
Conditions
HIV Infections
Interventions
Indinavir sulfate, Abacavir sulfate, Nelfinavir mesylate, Efavirenz, Levocarnitine, Adefovir dipivoxil, Lamivudine, Stavudine, Zidovudine, Didanosine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
16 Years and older
Enrollment
440 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2003
U.S. locations
52
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 32 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2021 · Synced Sep 2, 2026, 1:45 PM EDT
Completed Phase 3 Interventional

A Study of Three Drugs Plus Zidovudine in the Prevention of Infections in HIV-Infected Patients

NCT00000991
View directory record Official record
Conditions
Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions
Pentamidine isethionate, Sulfamethoxazole-Trimethoprim, Dapsone, Zidovudine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1994
U.S. locations
20
States / cities
Los Angeles, California • Oakland, California • San Diego, California + 15 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Sep 2, 2026, 1:45 PM EDT
Completed Phase 2 Interventional

Safety and Effectiveness of Adding PMPA Prodrug to an Anti-HIV Drug Combination to Treat HIV-Infected Patients

NCT00002415
View directory record Official record
Conditions
HIV Infections
Interventions
Tenofovir disoproxil fumarate
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
24
States / cities
Birmingham, Alabama • Phoenix, Arizona • Berkeley, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 2, 2026, 1:45 PM EDT
Completed Phase 1 Interventional

HIV Prevention in Very High Risk Men Who Have Sex With Men

NCT01291589
View directory record Official record
Conditions
Risk Reduction Behavior
Interventions
Cognitive-behavioral therapy
Behavioral
Lead sponsor
Fenway Community Health
Other
Eligibility
18 Years and older · Male only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 8, 2016 · Synced Sep 2, 2026, 1:45 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of COBI-boosted Atazanavir Versus Ritonavir-boosted Atazanavir Each Administered With Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults

NCT01108510
View directory record Official record
Conditions
HIV, HIV Infections
Interventions
COBI, RTV, ATV, FTC/TDF, COBI placebo, RTV placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
698 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
64
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 42 more
Source: ClinicalTrials.gov public record
Updated May 22, 2016 · Synced Sep 2, 2026, 1:45 PM EDT
Terminated Phase 3 Interventional

Screening Protocol To Determine Eligibility For Studies Of The Chemokine Coreceptor 5 (CCR5) Antagonist GW873140

NCT00123890
View directory record Official record
Conditions
HIV Infection
Interventions
GW873140
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
34
States / cities
Tucson, Arizona • Laguna Beach, California • Long Beach, California + 30 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2011 · Synced Sep 2, 2026, 1:45 PM EDT
Completed Phase 1 Interventional

Safety, Tolerability, and Anti-HIV Activity of PEG-Intron in HIV-Positive Children

NCT00006325
View directory record Official record
Conditions
HIV Infections
Interventions
Peginterferon alfa-2b
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
3 Months to 16 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2004
U.S. locations
15
States / cities
Long Beach, California • Los Angeles, California • San Francisco, California + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2021 · Synced Sep 2, 2026, 1:45 PM EDT
Terminated No phase listed Observational

Setting up a Blood Bank for Gene Therapy in HIV-Infected Infants

NCT00000917
View directory record Official record
Conditions
HIV Infections, Pregnancy
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
1 Day to 6 Months
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
8
States / cities
La Jolla, California • Long Beach, California • Los Angeles, California + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2008 · Synced Sep 2, 2026, 1:45 PM EDT
Completed Not applicable Interventional

A Multi-Center, Placebo-Controlled, Double-Blind, Randomized Trial Comparing the Virologic and Immunologic Activities of 400 Mg Nevirapine in Combination With Zidovudine Versus Zidovudine Alone in Asymptomatic HIV-1 Infected Patients With 4-12 Months of Prior Zidovudine Therapy and 200-500 CD4+ Cell

NCT00002323
View directory record Official record
Conditions
HIV Infections
Interventions
Nevirapine, Zidovudine
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
13 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
5
States / cities
Oakland, California • Chicago, Illinois • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 2, 2026, 1:45 PM EDT
Completed Not applicable Interventional Results available

Poor Sleep and Inflammation in HIV-Infected Adults

NCT03848325
View directory record Official record
Conditions
HIV-1-infection, Sleep Deprivation, Inflammation
Interventions
Sleep deprivation
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 28, 2023 · Synced Sep 2, 2026, 1:45 PM EDT
Terminated Phase 3 Interventional

Study Of Chemokine Coreceptor 5 (CCR5) Antagonist GW873140 In R5/X4-Tropic Treatment-Experienced HIV-Infected Subjects

NCT00197197
View directory record Official record
Conditions
HIV Infection
Interventions
GW873140
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
11
States / cities
Los Angeles, California • Norwalk, Connecticut • Fort Lauderdale, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2011 · Synced Sep 2, 2026, 1:45 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of IMVAMUNE® (MVA-BN®) Smallpox Vaccine in HIV Infected Patients

NCT00316589
View directory record Official record
Conditions
HIV Infections
Interventions
IMVAMUNE (MVA-BN)
Biological
Lead sponsor
Bavarian Nordic
Industry
Eligibility
18 Years to 55 Years
Enrollment
581 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2009
U.S. locations
34
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Burbank, California + 29 more
Source: ClinicalTrials.gov public record
Updated Jan 2, 2019 · Synced Sep 2, 2026, 1:45 PM EDT
Terminated Phase 1 Interventional

Study of Valproic Acid to Treat HIV Infected Adults

NCT00312546
View directory record Official record
Conditions
HIV Infections
Interventions
Enfuvirtide, Valproic acid
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 13, 2012 · Synced Sep 2, 2026, 1:45 PM EDT
Completed Not applicable Interventional

A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Adefovir Dipivoxil When Added to Standard Antiretroviral Therapy for the Treatment of HIV-Infected Patients With CD4 Cell Counts >= 200/mm3

NCT00002161
View directory record Official record
Conditions
HIV Infections
Interventions
Adefovir dipivoxil
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
13 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
27
States / cities
Birmingham, Alabama • Berkeley, California • Los Angeles, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 2, 2026, 1:45 PM EDT
Completed Not applicable Interventional

Immune System Function Following Vaccination in HIV Infected Children Taking Anti-HIV Drugs

NCT00257127
View directory record Official record
Conditions
HIV Infections
Interventions
Pneumococcal 7-valent conjugate vaccine, Pneumococcal polysaccharide vaccine, Hepatitis B vaccine, Measles, mumps, and rubella virus vaccine, live
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
6 Years to 23 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
24
States / cities
Birmingham, Alabama • Alhambra, California • Long Beach, California + 17 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2021 · Synced Sep 2, 2026, 1:45 PM EDT
Completed Phase 1 Interventional Results available

Phase 1, Open-label, Single Dose Study to Examine Safety, Tolerability, Pharmacokinetics and Virologic Impact of VRC01LS or VRC07-523LS in HIV-infected Viremic Adults

NCT02840474
View directory record Official record
Conditions
HIV-1
Interventions
VRC-HIVMAB080-00-AB, VRC-HIVMAB075-00-AB
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 70 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
6
States / cities
Birmingham, Alabama • Los Angeles, California • St Louis, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2025 · Synced Sep 2, 2026, 1:45 PM EDT
Completed No phase listed Observational

A Study of Anal Cancer Development in HIV Infected People

NCT00107679
View directory record Official record
Conditions
HIV Infections, Anus Neoplasms
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
560 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
13
States / cities
Los Angeles, California • San Francisco, California • Denver, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2014 · Synced Sep 2, 2026, 1:45 PM EDT
Completed Phase 2 Interventional Results available

Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome & Immune Activation Markers

NCT02706717
View directory record Official record
Conditions
HIV-1 Infection
Interventions
Visbiome Extra Strength, Placebo
Drug
Lead sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Network
Eligibility
18 Years and older
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
24
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2020 · Synced Sep 2, 2026, 1:45 PM EDT
Completed Phase 3 Interventional Results available

A Study to Compare Effectiveness and Safety of Darunavir/Ritonavir (DRV/Rtv) 800mg/100mg Once Daily Versus DRV/Rtv 600mg/100mg Twice Daily in Early Treatment-Experienced HIV-1 Infected Patients (ODIN)

NCT00524368
View directory record Official record
Conditions
Human Immunodeficiency Virus - Type 1
Interventions
Darunavir (DRV), Ritonavir (rtv)
Drug
Lead sponsor
Tibotec Pharmaceuticals, Ireland
Industry
Eligibility
18 Years and older
Enrollment
590 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
30
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Beverly Hills, California + 27 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2013 · Synced Sep 2, 2026, 1:45 PM EDT
Not listed Phase 3 Interventional

Comparing Side Effects of Two Forms of Videx in HIV-Infected Adults

NCT00008489
View directory record Official record
Conditions
HIV Infections
Interventions
Didanosine
Drug
Lead sponsor
PharmaResearch
Industry
Eligibility
16 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
15
States / cities
Los Angeles, California • San Francisco, California • Washington D.C., District of Columbia + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 2, 2026, 1:45 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

The Use of Bacteriophage Phi X174 to Assess the Immune Competence of HIV-Infected Patients In Vivo

NCT00001540
View directory record Official record
Conditions
HIV Infections
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1996 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 2, 2026, 1:45 PM EDT
Completed Phase 1 Interventional

The Safety and Effectiveness of Hydroxyurea and ddI Used Individually or Together in HIV-Infected Patients

NCT00001074
View directory record Official record
Conditions
HIV Infections
Interventions
Hydroxyurea, Didanosine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2000
U.S. locations
18
States / cities
San Diego, California • San Francisco, California • Stanford, California + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2021 · Synced Sep 2, 2026, 1:45 PM EDT
Completed Phase 3 Interventional Results available

Safety & Immunogenicity of 13vPnC in HIV-Infected Subjects Aged 18 or Older Who Were Previously Immunized With 23vPS

NCT00963235
View directory record Official record
Conditions
HIV Infections, Pneumococcal Infections
Interventions
13-valent pneumococcal conjugate vaccine, Blood draw
Biological · Procedure
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
331 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
15
States / cities
San Francisco, California • Aurora, Colorado • Washington D.C., District of Columbia + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2013 · Synced Sep 2, 2026, 1:45 PM EDT
Completed Phase 4 Interventional Results available

Anti-HIV Medications for People Recently Infected With HIV

NCT00106171
View directory record Official record
Conditions
HIV Infections
Interventions
Highly active antiretroviral therapy (HAART)
Drug
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
18 Years and older
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 12, 2023 · Synced Sep 2, 2026, 1:45 PM EDT